4. Target of rapamycin inhibitors (TOR‐I) versus antimetabolite: comparison in outcomes between 2006 review and 2019 update.

Outcomes	2006 review (11 studies)	2019 update (33 studies)
Death	No difference	No difference
All graft loss	No difference	No difference
Graft loss censored for death	No difference	No difference
All acute rejection	Reduced with TOR‐I	No difference
Biopsy‐proven acute rejection	Reduced with TOR‐I	No difference
CMV infection	Reduced with TOR‐I	Reduced with TOR‐I
Wound complications	Increased with TOR‐I	Increased with TOR‐I
Malignancies	No difference	No difference
Need to change treatment	No difference	Increased with TOR‐I
New‐onset diabetes mellitus	No difference	Increased with TOR‐I
Lymphoma/PTLD	No difference	No difference
BK virus infection	Not reported	Lower with TOR‐I
Tremor	No difference (1 study)	No difference
Acne/rash	Increased with TOR‐I (1 study)	Increased with TOR‐I
GFR	Reduced with TOR‐I	Reduced with TOR‐I
SCr	Increased with TOR‐I	Increased with TOR‐I
Hypercholesterolaemia	Increased with TOR‐I	Increased with TOR‐I
Hypertriglyceridaemia	Increased with TOR‐I	Increased with TOR‐I
Leucopenia	Reduced with TOR‐I	Reduced with TOR‐I
Thrombocytopenia	Increased with TOR‐I	Increased with TOR‐I

Change in results have been highlighted

CMV ‐ cytomegalovirus; GFR ‐ glomerular filtration rate; PTLD ‐ post‐transplant lymphoproliferative disease; SCr ‐ serum creatinine